Bioengineers have repurposed a “non-working” CRISPR system to make a smaller version of the genome engineering tool. Its diminutive size should make it easier to deliver into human cells, tissues and the body for gene therapy.
Genetically engineered animals provide important insights into the molecular basis of health and disease. Research has focused mainly on genetically modified mice, although other species, such as pigs, are more similar to human physiology. Researchers at the Technical University of Munich (TUM) have now generated chickens and pigs in which target genes in desired organs can be efficiently altered.
The CRISPR-based gene editor, CGBE, opens up treatment avenues for up to 40 per cent of genetic disorders caused by single-nucleotide mutations.
Gene editing for the development of new treatments, and for studying disease as well as normal function in humans and other organisms, may advance more quickly with a new tool for cutting larger pieces of DNA out of a cell’s genome, according to a new study by UC San Francisco scientists.
Researchers at ETH Zurich have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously.